North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:North China Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014101
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Group Corp (NCPC) is a healthcare products provider that manufactures and distributes antibiotic bulks and formulations, vitamins and nutrition products. The company’s products comprise antibiotics, penicillin, amoxicillin, streptomycin sulfate, cefradine, 7-ADCA, vitamin C and vitamin B12. It offers its products in dosage forms of capsules, granules, injections, freeze-dried powder for injection, immunologic and biologic agent, nutrition supplement, tablets, veterinary and biocides products, powder for injection, antineoplastic agents, oral suspension and other formulations. The company markets its products across China. NCPC is headquartered in Shijiazhuang, China.

North China Pharmaceutical Group Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 11
Debt Offering 12
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 12
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 13
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 14
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 16
Acquisition 17
NCPC To Sell North China Pharma Huasheng For US$12 Million 17
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 18
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 19
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 20
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 21
North China Pharmaceutical Group Corp – Key Competitors 22
North China Pharmaceutical Group Corp – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 12
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 13
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 14
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 16
NCPC To Sell North China Pharma Huasheng For US$12 Million 17
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 18
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 19
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 20
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 21
North China Pharmaceutical Group Corp, Key Competitors 22
North China Pharmaceutical Group Corp, Other Locations 23
North China Pharmaceutical Group Corp, Subsidiaries 23

★海外企業調査レポート[North China Pharmaceutical Group Corp-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cincinnati Bell Inc.:企業の戦略・SWOT・財務情報
    Cincinnati Bell Inc. - Strategy, SWOT and Corporate Finance Report Summary Cincinnati Bell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mitsubishi Chemical Corp:企業の戦略的SWOT分析
    Mitsubishi Chemical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Achillion Pharmaceuticals Inc (ACHN):製薬・医療:M&Aディール及び事業提携情報
    Summary Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients …
  • Fresenius Kabi AG:企業の戦略的SWOT分析
    Fresenius Kabi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • C&S Wholesale Grocers, Inc.
    C&S Wholesale Grocers, Inc. - Strategy, SWOT and Corporate Finance Report Summary C&S Wholesale Grocers, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Engie Brasil Energia SA (EGIE3):電力:M&Aディール及び事業提携情報
    Summary Engie Brasil Energia SA (Engie Brasil), formerly Tractebel Energia SA, a subsidiary of Engie SA, undertakes the generation and commercialization of electricity. It generates energy through various source of energy such as hydro; thermal; and complementary energy sources including wind, solar …
  • EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient a …
  • Genextra Spa:製薬・医療:M&Aディール及び事業提携情報
    Summary Genextra SpA (Genextra) is a therapies developing company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, INT- 777 for metabolic syndrome, mono therapy and diabetes, novel HDAC and HSP90 inhibitors for the treatment of canc …
  • Valeant Canada LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Valeant Canada LP (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical products manufacturing company. The company offers products such as aczone, airomir, aldara, benzaclin topical gel, benzamycin, biacna topical gel, C.E.S. tablets, carbolith, ca …
  • Prothena Corp Plc (PRTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Prothena Corp Plc (Prothena) is a clinical biotechnology company, which discovers, develops and markets novel medicines that are indicated for the treatment of diseases associated with neuroscience and orphan diseases. The company develops monoclonal antibodies directed specifically at disea …
  • Dassault Aviation SA (AM):企業の財務・戦略的SWOT分析
    Dassault Aviation SA (AM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CMIC Holdings Co Ltd (2309):企業の財務・戦略的SWOT分析
    Summary CMIC Holdings Co Ltd (CMIC) is a contract research organization that supports drug development services. The organization offers medical research related services to pharmaceuticals and medical organizations. Its CRO business services include monitoring, data management, STAT analysis, regis …
  • Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford BioTherapeutics Ltd (OBT) is a clinical stage oncology company that develops antibody drug conjugates for the treatment of variety of cancers. The company’s product pipelines currently includes T-cell based IO therapies including check point modulators; NK cell based IO therapies such …
  • EpiVax Inc-製薬・医療分野:企業M&A・提携分析
    Summary EpiVax Inc (EpiVax) is an immunology company which develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear se …
  • Atlas Genetics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Atlas Genetics Ltd (Atlas Genetics) is an in vitro diagnostics company that offers decentralised, near-patient and point of care testing services. The company develops and offers diagnostic platforms such as io system and callisto system. Its io system is a diagnostic instrument and disposab …
  • Sun Pharmaceutical Industries Ltd (SUNPHARMA):医療機器:M&Aディール及び事業提携情報
    Summary Sun Pharmaceutical Industries Ltd (Sun Pharma) is a specialty pharmaceutical company, which offers a wide range of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s products find application in the treatment of various conditions related to psych …
  • Urban One Inc (UONEK):企業の財務・戦略的SWOT分析
    Urban One Inc (UONEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Invuity Inc (IVTY):企業の財務・戦略的SWOT分析
    Summary Invuity Inc (Invuity) is a medical technology company that develops and markets advanced surgical devices for the minimally invasive and minimal access procedures. The company offers illuminated surgical retractors, single-use handheld aspiration and universal drop-in intracavity illuminator …
  • Shinva Medical Instrument Co Ltd (600587):企業の財務・戦略的SWOT分析
    Shinva Medical Instrument Co Ltd (600587) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Cimentos de Portugal SGPS SA:企業の戦略的SWOT分析
    Cimentos de Portugal SGPS SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆